Peptidoglycan (Cutibacterium acnes) (PGN)

Peptidoglycan is a fundamental structural component of the Cutibacterium acnes cell wall, providing the mechanical strength necessary to withstand internal osmotic pressure (Schleifer & Kandler, 1972). It consists of a glycan backbone of alternating N-acetylglucosamine and N-acetylmuramic acid residues cross-linked by short peptides. In the context of acne vulgaris, C. acnes peptidoglycan acts as a potent pro-inflammatory mediator by serving as a ligand for pattern recognition receptors such as Toll-like receptor 2 (TLR2) and NOD2 on keratinocytes and immune cells (Kim et al., 2002; Nagy et al., 2005). This interaction triggers the release of various cytokines, including IL-1β, IL-8, and TNF-α, which contribute to the inflammatory lesions characteristic of the disease (Graham et al., 2004). Therapeutically, peptidoglycan is a primary target for several classes of antibiotics, most notably beta-lactams and glycopeptides, which interfere with its synthesis and assembly (Kohanski et al., 2010). These drugs typically bind to penicillin-binding proteins (PBPs), preventing the final transpeptidation step of cell wall synthesis. Additionally, enzymes like lysozyme can directly degrade the peptidoglycan polymer, leading to bacterial lysis and death (Raghavan & Shah, 2015). Understanding the role of this molecule is crucial for developing treatments that not only kill the bacteria but also mitigate the inflammatory response it induces. The persistence of peptidoglycan fragments in the skin can also lead to chronic inflammation even after the bacteria are no longer viable. Thus, targeting the synthesis or degradation of C. acnes peptidoglycan remains a cornerstone of dermatological pharmacology.

Other names

MureinPropionibacterium acnes peptidoglycanC. acnes cell wall peptidoglycanBacterial cell wall peptidoglycan

Inhibition of peptidoglycan cross-linking (transpeptidation) via penicillin-binding proteins (PBPs) or direct enzymatic hydrolysis of the glycan backbone.